Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching US$2.51 billion in 2024 and an impressive US$6.73 billion by 2029.

A Pseudonym for Protection As a healthcare professional, I write under a pseudonym, not because I want to remain anonymous, ...